MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The role of microRNA-365 (miR-365) in ovarian cancer development is largely unknown.
• Previous studies indicate miR-365's involvement in tumorigenesis across various cancers.
• Ovarian cancer remains a significant global health challenge requiring novel therapeutic strategies.

Purpose of the Study:

• To investigate the function and molecular mechanisms of miR-365 in ovarian cancer.
• To determine the relationship between miR-365 expression and clinicopathological features of ovarian cancer.
• To identify potential therapeutic applications of miR-365 in ovarian cancer.

Main Methods:

• Quantitative real-time PCR (qPCR) and Western blot analysis to assess miR-365 and Wnt5a expression.
• Functional assays including cell proliferation, colony formation, migration, and invasion assays.
• Bioinformatic analysis, luciferase reporter assays, and xenograft mouse models to validate miR-365 targets and mechanisms.

Main Results:

• miR-365 expression was significantly downregulated in ovarian cancer tissues and cell lines.
• Low miR-365 expression correlated with advanced FIGO stage, poor histological grade, and lymph node metastasis.
• miR-365 mimic transfection inhibited ovarian cancer cell proliferation, migration, and invasion.
• Wnt5a was identified as a direct target of miR-365, with inverse correlation in patient tissues.
• Wnt5a overexpression reversed the anti-proliferative and anti-invasive effects of miR-365.
• In vivo studies confirmed that miR-365 overexpression suppressed tumor growth by repressing Wnt5a.

Conclusions:

• miR-365 functions as a tumor suppressor in ovarian cancer by inhibiting proliferation, migration, and invasion.
• The miR-365/Wnt5a axis plays a critical role in ovarian cancer progression.
• miR-365 represents a potential biomarker and therapeutic target for ovarian cancer.